is paying Sirna Therapeutics $12 million up front as part of a joint effort to develop therapeutics to treat respiratory diseases. Other WRAL Top Stories The drugs would be based on RNA interference ...
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results